A 16-year retrospective study on fungal prevalence and diversity in patients with Cystic Fibrosis- Candida dubliniensis was associated with a decline in lung function.

[1]  C. Brandt,et al.  Aspergillus Bronchitis in Patients with Cystic Fibrosis , 2018, Mycopathologia.

[2]  V. Chrenkova,et al.  Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis , 2017, Mycopathologia.

[3]  S. Ranque,et al.  Aspergillus fumigatus in cystic fibrosis: An update on immune interactions and molecular diagnostics in allergic bronchopulmonary aspergillosis , 2017, Allergy.

[4]  P. Chandra,et al.  Persistence of Candida dubliniensis and lung function in patients with cystic fibrosis , 2017, BMC Research Notes.

[5]  S. Suerbaum,et al.  Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. , 2016, Medical mycology.

[6]  P. Burgel,et al.  Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy , 2016, Infection and drug resistance.

[7]  E. Kerem,et al.  Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis , 2015, Pediatric pulmonology.

[8]  N. Simmonds,et al.  Aspergillus and cystic fibrosis: old disease – new classifications , 2014, Current opinion in pulmonary medicine.

[9]  N. McElvaney,et al.  Fungi in the cystic fibrosis lung: bystanders or pathogens? , 2014, The international journal of biochemistry & cell biology.

[10]  T. Boekhout,et al.  High prevalence of Candida dubliniensis in lower respiratory tract secretions from cystic fibrosis patients may be related to increased adherence properties. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[11]  G. Feierl,et al.  Modified culture method detects a high diversity of fungal species in cystic fibrosis patients. , 2013, Medical mycology.

[12]  A. Prince,et al.  Cystic fibrosis: a mucosal immunodeficiency syndrome , 2012, Nature Medicine.

[13]  N. McElvaney,et al.  Radiological abnormalities associated with Aspergillus colonization in a cystic fibrosis population. , 2012, European journal of radiology.

[14]  M. Bonten,et al.  Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  N. McElvaney,et al.  Candida species in cystic fibrosis: A road less travelled. , 2010, Medical mycology.

[16]  K. Bennett,et al.  Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis. , 2010, Chest.

[17]  S. Ranque,et al.  Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. , 2010, Medical mycology.

[18]  K. Carroll,et al.  Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  S. Aaron,et al.  The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. , 2010, Chest.

[20]  J. Elborn,et al.  Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. , 2010, Medical mycology.

[21]  S. Freedman,et al.  Cystic fibrosis , 2009, The Lancet.

[22]  H. Einsele,et al.  Identification of medically important fungi by the PyrosequencingTM technology , 2004, Mycoses.

[23]  F. Ratjen,et al.  Cystic fibrosis , 2003, The Lancet.

[24]  B. Strandvik,et al.  Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF , 2001 .

[25]  S. Donnelly,et al.  Recovery of Candida dubliniensisfrom Non-Human Immunodeficiency Virus-Infected Patients in Israel , 2000, Journal of Clinical Microbiology.

[26]  B. Ramsey,et al.  Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. , 1999, The Journal of infectious diseases.

[27]  W. Merz,et al.  Identification of Candida dubliniensisin a Prospective Study of Patients in the United States , 1999, Journal of Clinical Microbiology.

[28]  M. Henman,et al.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro , 1997, Antimicrobial agents and chemotherapy.

[29]  C. Milla,et al.  Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients , 1996, Pediatric pulmonology.

[30]  D. Coleman,et al.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. , 1995, Microbiology.

[31]  H. Novey,et al.  Incidence of serum antibodies to several Aspergillus species and to Candida albicans in cystic fibrosis. , 1976, The American review of respiratory disease.